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Human immunodeficiency virus type 1 (HIV-1) infection in mononuclear phagocyte lineage cells (monocytes,
macrophages, and microglia) is a critical component in the pathogenesis of viral infection. Viral replication in
macrophages serves as a reservoir, a site of dissemination, and an instigator for neurological sequelae during
HIV-1 disease. Recent studies demonstrated that chemokine receptors are necessary coreceptors for HIV-1
entry which determine viral tropism for different cell types. To investigate the relative contribution of the
b-chemokine receptors CCR3 and CCR5 to viral infection of mononuclear phagocytes we utilized a panel of
macrophage-tropic HIV-1 strains (from blood and brain tissue) to infect highly purified populations of
monocytes and microglia. Antibodies to CD4 (OKT4A) abrogated HIV-1 infection. The b chemokines and
antibodies to CCR3 failed to affect viral infection of both macrophage cell types. Antibodies to CCR5 (3A9)
prevented monocyte infection but only slowed HIV replication in microglia. Thus, CCR5, not CCR3, is an
essential receptor for HIV-1 infection of monocytes. Microglia express both CCR5 and CCR3, but antibodies
to them fail to inhibit viral entry, suggesting the presence of other chemokine receptors for infection of these
cells. These studies demonstrate the importance of mononuclear phagocyte heterogeneity in establishing HIV-1
infection and persistence.
viral dissemination in nonlymphoid tissues. The unique antigenic expression of chemokine receptors on microglia may
render these cells susceptible to strains of HIV-1 that could
evolve over time into neurotropic strains.
To investigate the role of b-chemokine receptors in HIV-1
infection of microglia, we utilized highly purified cell systems
to analyze the early events of the viral life cycle after exposure
of chemokines, their receptors, and virus to monocytes and
microglia. The results demonstrated (i) that CCR5 and CCR3
are expressed by both monocytes and microglia, (ii) that these
receptors are expressed in both normal and encephalitic
brains, (iii) that CCR5, not CCR3, plays an essential role in
viral infection of monocytes, (iv) that HIV-1 infection of microglia occurs through receptors other than CCR5 and CCR3,
and (v) that the b chemokines themselves fail to alter viral
infection of monocytes or microglia. Taken together, these
data suggest that the two important macrophage-tropic HIV-1
receptors characterized to date, CCR5 and CCR3, are not
essential for HIV-1 infection of microglia, the principal phagocyte within the CNS.

CD4 and chemokine receptors are necessary cofactors for
human immunodeficiency virus type 1 (HIV-1) infection in its
natural target cells (1, 3, 11, 14, 16, 23). Macrophage- and
lymphocyte-tropic strains of HIV-1 utilize the chemokine receptors CCR5 (1, 3, 11, 14, 23) and CXCR4 (16), respectively,
for viral entry. The importance of chemokine receptors in
HIV-1 pathogenesis is demonstrated by the mutant allele of
CCR5 with a 32-bp deletion, D32. Individuals homozygous for
the mutant allele are highly resistant to HIV-1 infection, and
peripheral blood mononuclear cells (PBMC) isolated from
those individuals fail to support viral infection with macrophage-tropic strains (10, 25, 28, 32, 34, 36). Moreover, individuals heterozygous for this allele show slower progression to
AIDS. CCR5 was shown recently to be an essential coreceptor
for HIV-1 infection of monocytes, and resistance to macrophage-tropic HIV-1 infection was demonstrated with monocytes from D32-homozygous individuals (34).
Despite the rapid advances made in understanding the role
of chemokine receptors for HIV-1 infection, the interactions
between the virus and its principal host cells in the central
nervous system (CNS), the microglia, remain incompletely defined. Infection and replication of HIV-1 in brain macrophages
and microglia represent the principal reservoir and vehicle for

MATERIALS AND METHODS
Reagents. Antibodies to mouse immunoglobulin G (IgG) F(ab9)2 and IgM
F(ab9)2 fragments and rabbit IgG conjugated to fluorescein isothiocyanate, tetramethyl rhodamine isothiocyanate, and rhodamine, respectively, were utilized.
These were purchased from Boehringer Mannheim Corp., Indianapolis, Ind.
Antibodies to CD68, glial fibrillary acidic protein (GFAP), HIV-1 p24, von Willebrand factor, and HAM-56 were obtained from Dako Corp., Carpinteria, Calif.
Chemokine peptides macrophage inflammatory protein 1 alpha (MIP-1a),
MIP-1b, and regulated upon activation T-cell expressed and secreted (RANTES) were obtained from R & D Systems, Minneapolis, Minn. Eotaxin was
purchased from PeproTech Inc., Rocky Hill, N.J. Antibodies to CCR5 and CCR3
(23) were supplied by LeukoSite Inc., Cambridge, Mass.
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TABLE 1. PCR primers used for assay of b-chemokine receptor expression

Receptor or
standarda

Nucleotides

Primer

CCR5 (278)

2785–2802
3043–3063
2946–2964

Sense
Antisense
Probe

TACCAGCCTCCGTATTTC
TTACTATTCCCTCACCTTACC
AAAAAACCTCTCTCTCTCC

CCR3 (234)

592–613
804–823
766–785

Sense
Antisense
Probe

CCCAGAGGATACAGTTATATATGC
GATAGGAGAGAGAAGGATAGC
AGAAAATGAAAAACACCGCC

GAPDH (195)

199–217
394–374
280–299

Sense
Antisense
Probe

CCATGGAGAAGGCTGGGG
CAAAGTTGTCATGGATGACC
CTGCACCACCACTGCTTAGC

a

Sequence

Numbers in parentheses are the base pairs in the associated cDNA.

Viral isolates. HIV-1JR-FL (30) was obtained from the AIDS Research and
Reference Reagent Program, National Institute of Allergy and Infectious Diseases. It was previously isolated from brain tissue of an HIV-1-infected individual
with encephalitis. HIV-1ADA was isolated from PBMC of an individual with
AIDS and was propagated as previously described (18). HIV-1YU-2 was obtained
from genomic DNA from encephalitic brain tissue (27) and was rescued by
transfecting the proviral DNA into a 293T packaging system (33). All isolates
were prepared as viral stocks free of mycoplasma and endotoxin contamination.
Standardized viral inocula (0.1 infectious viral particle/cell) were used for infections (18).
Brain autopsy material. Brain tissue obtained by autopsy from patients who
died of HIV-1 encephalitis and control (HIV-1-seronegative) tissue were used
for immunological assessment of b-chemokine receptors (29). Pieces of brain
tissue were removed from the frontal, temporal, and occipital lobes, the basal
ganglia, the hippocampus, the cerebellum, and the medulla oblongata and were
snap frozen at autopsy. Eight-micrometer-thick serial frozen sections were prepared for immunohistochemistry. Morphological features of HIV-1 encephalitis
included the presence of multinucleated giant cells and perivascular macrophages, the formation of microglial nodules, and astrogliosis. Brain tissue specimens from two patients who died of carcinoma of the lung and hepatic failure
(HIV-1 seronegative) were used as additional controls. These specimens have
minimal neuropathological changes. Immunohistochemical evaluations for the
levels of macrophage and microglia activation and viral infection were confirmed
with antibodies to CD68, HAM-56, HLA-DR, and HIV-1 p24 antigens. The
extent of astrogliosis (GFAP) and chemokine receptor antigen expression were
assayed by indirect immunofluorescence (IF) assay as previously described (29).
Double immunostaining was utilized to colocalize b-chemokine receptors and
cellular antigens (HAM-56 and GFAP) in the human brain tissues.
Isolation and cultivation of primary human monocytes and microglia. PBMC
obtained from HIV-1-, HIV-2-, and hepatitis B virus-seronegative donors by
leukopheresis were purified by countercurrent centrifugal elutriation (18). Cells
were .98% monocytes as determined by Wright and nonspecific esterase staining. Adherent monolayers were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma Chemical Co., St. Louis, Mo.) supplemented with 10% human
serum and 1,000 U of highly purified recombinant macrophage colony stimulating factor (MCSF) per ml, a generous gift from Genetics Institute, Cambridge,
Mass.
Fetal brain tissue (gestational age, 14 to 20 weeks) was obtained from elective
abortions performed in full compliance with National Institutes of Health and
University of Nebraska Medical Center ethical guidelines. Microglia were isolated and purified as previously described (2). Briefly, brain tissue was obtained
and then dissociated with 0.25% trypsin for 30 min at 37°C. The resulting
single-cell suspension was cultured in DMEM (Sigma Chemical Co.) supplemented with 10% fetal bovine serum and 1,000 U of MCSF per ml. After 14 days
in culture, the nonadherent microglia cells were collected and purified by preferential adhesion. These procedures resulted in .98%-pure microglial cell populations (2).
HIV-1 infection. Cells (monocytes and microglia) were cultured for 7 days
prior to viral inoculation. Monocytes and microglia were cultivated at densities of
5
10 and 5 3 104 cells/well, respectively, in 96-well plates (Costar Corp., Cambridge, Mass.). Cells were inoculated with 0.1 infectious viral particle/cell. Cells
were preincubated with antibodies to CCR5 (3A9; 100 mg/ml), CCR3 (20 mg/ml),
or CD4 (OKT4A; 10 mg/ml) or with the b-chemokine peptides (500 ng/ml) for
1 h at 37°C and then exposed to the virus for an additional 4 h in the presence
of the antibodies or peptides. After virus exposure, the medium was replaced
with that supplemented with chemokine receptor antibodies and peptides at the
exact concentrations used during the initial inoculations. Samples were obtained
every 2 or 3 days for assay of reverse transcriptase (RT) activity. RT activity was
determined by incubating 10 ml of sample with a reaction mixture consisting of
0.05% Nonidet P-40 (Sigma) and [3H]dTTP (2 Ci/mmol; Amersham Corp.,

Arlington Heights, Ill.) in Tris-HCl buffer (pH 7.9) for 24 h at 37°C. Radiolabeled nucleotides were precipitated on paper filters in an automatic cell harvester (Skatron, Sterling, Va.) by using cold 10% trichloroacetate and 95%
ethanol. Incorporated activity was measured by liquid scintillation spectroscopy
(26).
PCR analysis of viral DNA. Monocytes and microglia were propagated and
infected with virus in the presence or absence of b chemokines or their receptors
as described above. Prior to infection, the HIV-1 stock virus was treated with
DNase I for 30 min to eliminate contaminating viral DNA (44). At 8 and 96 h
following infection, culture fluids were withdrawn for assay of RT activity and the
cells were scraped in 1 ml of phosphate-buffered saline. Total cellular DNA was
extracted from the cell pellet and resuspended at a concentration of 104 cell
equivalents/ml. PCR was performed to quantitate the early, intermediate, and
late events of proviral DNA synthesis with primers to long terminal repeat (LTR)
U3/R, pol I and J, and LTR U3/gag regions of the viral genome. Standard HIV-1
DNAs for quantitation were prepared by amplification of serial twofold dilutions
of DNA extracted from 8e5 cells (17). Tubulin was used as the internal standard.
Amplified products of viral DNA were hybridized to radiolabeled oligonucleotide probes and quantified on a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.).
RNA PCR assays for b-chemokine receptor gene expression. Total cellular
RNA was isolated with TRIzol reagent (Life Technologies). Cells were lysed by
repetitive pipetting in 1 ml of TRIzol reagent per 5 to 10 million cells. RNA was
extracted with chloroform and precipitated with isopropanol (4, 5). DNA-free
RNA was then precipitated with 3 M sodium acetate and ethanol. To verify the
absence of DNA contamination, DNA PCR assays for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were performed on the cellular RNA preparations. Levels of chemokine mRNAs were examined after reverse transcription
with antisense primers and PCR amplification of cDNA. Table 1 summarizes the
primers used in this study. GAPDH RNA served as an internal standard for
quantitation. The products of 28 cycles of amplification (30 s, 94°C; 30 s, 50°C;
60 s, 72°C) were analyzed by Southern blot hybridization with specific 32P-labeled
oligonucleotides (35).
Immunocytochemical assays. Adherent monolayers of microglia or monocytes
were cultured (as described above) in 8-mm Chamber-Tech slides. The cells were
fixed in ice-cold acetone-methanol (1:1) for 20 min after 7 days of culture and
then incubated with antibodies to CCR3, CCR5, HAM-56, GFAP, or von Willebrand factor at a dilution of 1:100, 1:50, 1:50, 1:200, or 1:200, respectively.
Anti-mouse IgG F(ab9)2 fragments conjugated to fluorescein isothiocyanate were
used for CCR5 and CCR3 detection. Anti-mouse IgM–tetramethyl rhodamine
isothiocyanate conjugate was used for HAM-56, whereas rhodamine-conjugated
anti-rabbit IgG was used for GFAP and von Willebrand factor detection. All
secondary antibodies were purchased from Boehringer Mannheim Corp. Double
immunostainings were performed to colocalize chemokine receptors with cellspecific antigens. Direct application of secondary antibodies was performed as a
negative control for this assay.
Nucleotide sequence accession numbers. The cDNA sequences used for the
design of RT-PCR primers were obtained from GenBank. For CCR5, the complete cDNA sequence of human chemokine receptor 5 mRNA was listed under
accession no. U54994 and that of human eosinophil chemokine receptor 3
mRNA was listed under accession no. U28694.

RESULTS
Expression of CCR5 and CCR3 on primary human monocytes and microglia. To investigate the role of CCR5 and
CCR3 as receptors for HIV-1 infection, we examined the ex-
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FIG. 1. Expression of chemokine receptors on human monocytes. Monocytes were recovered from PBMC of HIV- and hepatitis B virus-seronegative donors after
leukopheresis, purified by countercurrent centrifugal elutriation, and cultured for 7 days before immunocytochemical evaluation. Cell suspensions were .98%
monocytes by the criteria of cell morphology in the Wright-stained cytosmears and by CD68 and HAM-56 immunostaining (macrophage markers). Expression of CCR3
was detected on the cell membranes and in the cytoplasm of HAM-56-positive monocytes (A and B). A similar distribution of CCR5 immunostaining was found on
human monocytes double immunolabeled for HAM-56 (C and D). The application of the secondary antibodies (Abs) only (negative control) did not produce detectable
signals on the replicate cells (E and F). Panels A and B show double immunostaining with anti-CCR3 (7B11) and HAM-56 Abs; panels C and D show double
immunostaining with anti-CCR5 (5C7) and HAM-56 Abs; panels E and F display negative controls for which primary antibodies were omitted. Original magnification,
3200. The cellular antigens are visualized by IF assay. The results are representative of three independent experiments performed with three separate donors.
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FIG. 2. Expression of chemokine receptors on primary human microglia. Human fetal microglia (.98% pure) were cultured for 7 days in 8-mm Chamber-Tech
slides at a density of 50,000 cells/well. CCR3 expression was shown predominantly on cell membranes of HAM-56-immunoreactive microglia (A and D). Application
of the secondary antibodies (Abs) only (negative control) did not produce detectable staining on the replicate cells (E and F). Panels A and B show double
immunostaining with anti-CCR3 (7B11) and HAM-56 Abs; panels C and D show double immunostaining with anti-CCR5 (5C7) and HAM-56 Abs; panels E and F
display negative controls for which primary Abs were omitted. Original magnification, 3200. The cellular antigens are visualized by IF assay. The results are
representative of two independent experiments performed with two separate tissue donors.
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pression of the b-chemokine receptors in monocytes and microglia. Monocytes were recovered from PBMC by centrifugal
elutriation, and total cellular RNA was isolated after initial cell
isolation and after tissue culture propagation. CCR3 and
CCR5 mRNAs were identified by RT-PCR assays of monocytes from the time of cell isolation through cell differentiation
(during a 7-day cultivation period). The levels of both CCR5
and CCR3 transcripts increased with cellular differentiation
(data not shown). To substantiate the mRNA results, we examined the surface expression of CCR3 and CCR5 on cells
cultured for different time periods (1, 5, 7, and 10 days). The
b-chemokine receptor antigens were localized in association
with HAM-56, a macrophage-specific marker, by day 5 after
cell culture. CCR3 immunoreactivity was observed both on the
cell surface and in the cytoplasm of HAM-56 antigen-positive
cells (Fig. 1A and B). A similar distribution of CCR5 was also
seen (Fig. 1C and D). Thus, cultured monocytes expressed
both CCR5 and CCR3 (Fig. 1). Fluorescence-activated cell
sorter analysis of freshly isolated monocytes (data not shown)
showed only weak staining for CCR5 and little CCR3 expression, consistent with previous findings (24, 43). Intense staining
for CCR3 was observed on lymph node macrophages by immunohistochemistry (data not shown), similar to the pattern
reported previously for CCR5 (43).
To analyze the distribution of CCR3 and CCR5 in primary
human microglia, we isolated pure (.98%) populations of the
cells from fetal sources (2). CCR3 antigens were found predominantly on the cell membranes of the HAM-56-immunoreactive microglia (Fig. 2C and D). CCR5 was present both on
the cell membrane and in the microglial cytoplasm (Fig. 2A
and B). Thus, both monocytes and microglia express b-chemokine receptors CCR5 and CCR3.
Expression of b-chemokine receptors in HIV-1-encephalitic
and control brain tissues. In order to determine whether the
tissue culture analyses of CCR3 and CCR5 expression were
indicative of what is present in vivo, we analyzed CCR3 and
CCR5 production in HIV-1-infected and control brain tissues.
To assess the distribution of the chemokine receptors in the
human brain, 8-mm-thick serial frozen sections were cut from
the frontal cortex and basal ganglia of tissue obtained at autopsy from patients with encephalitis (three cases) and HIV1-seronegative controls (two cases). In all HIV-1-infected
tissues, neuropathological features of HIV-1 encephalitis, including macrophage infiltration, the presence of multinucleated giant cells, microglial nodules, and astrogliosis, were
found. Double immunostainings (for cell and chemokine receptor antigens) were performed to identify which brain cells
expressed CCR3 and CCR5. The majority of the identified
microglial cells and perivascular macrophages (identified by
HAM-56 immunoreactivity) expressed CCR3 (7B11) (Fig. 3A
and B). The identical cells expressed significant levels of cytoplasmic and membrane CCR5 antigen (5C7) (Fig. 3C and D).
Reactive astrocytes, identified by GFAP immunostaining, also
expressed CCR3 (Fig. 3E and F). Interestingly, the astrocytes
were uniformly CCR5 negative (Fig. 3G and H). The results
were reproduced in all five cases regardless of the presence of
HIV-1 infection or morphological signs of encephalitis. Primary human fetal astrocytes also expressed CCR3 transcripts
but not CCR5, consistent with the brain tissue findings (data
not shown).
Analysis of the effects of b chemokines and their receptors
on viral infection. (i) PCR analysis of HIV-1 DNA synthesis.
Confirmation of the expression of CCR3 and CCR5 on monocytes and microglia confirmed the notion that these cells could
use either or both of the b-chemokine receptors for viral entry.
To investigate this idea we utilized the b chemokines and their
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receptor antibodies to assess if viral infection could be inhibited in monocytes inoculated with macrophage-tropic strains
HIV-1ADA and HIV-1YU-2. The b-chemokine receptor antibodies and chemokine peptides were examined for whether
they could inhibit reverse transcription, the first step in establishment of HIV-1 infection. Antibodies to CD4 (OKT4A) and
the antiretroviral drug zidovudine (AZT), both known inhibitors of viral infection, were used as controls for the assay.
MIP-1a, MIP-1b, RANTES, and antibodies to CCR3 (7B11)
did not signficantly affect HIV-1ADA nucleic acid production.
Moreover, none of the chemokine peptides or receptor antibodies produced any significant or sustained inhibition of
HIV-1 reverse transcription as observed by a comparison to
results with CD4 antibodies or with AZT (data not shown).
To substantiate these findings, we repeated the PCR analyses with a viral isolate obtained from direct cloning of genomic
DNA from encephalitic brain tissue, HIV-1YU-2. Interestingly,
RANTES resulted in higher levels of late HIV-1 DNA products 96 h following monocyte inoculation with HIV-1YU-2 (Fig.
4). MIP-1a and MIP-1b peptides produced only a partial inhibition of viral DNA production. Antibodies to CCR3 did not
affect (to any significant degree) the levels of late products of
viral reverse transcription. However, antibodies to CCR5
(3A9) produced a marked inhibition of viral DNA, comparable
to that observed with antibodies to OKT4A and AZT. In
summary, although previous reports demonstrated an inhibition of macrophage-tropic HIV-1 infection by b chemokines
(31, 42), we found complete synthesis of HIV-1 proviral DNA
after such cell treatments. Antibodies to CCR5 alone were able
to inhibit viral infection. Because of the limitations in the
numbers of microglia recovered from fetal tissue, analysis of
viral infection could not be determined by viral DNA PCR and
was limited to the RT assays shown below.
(ii) RT assays for detection of progeny virions. To further
assess the role of antibodies to b chemokines and their receptors for HIV-1 infection of monocytes and microglia, we assayed the levels of progeny virion production by reverse transcriptase activity from infected cells. The assays were done
following exposure of cells to the b-chemokine peptides, receptor antibodies, and virus. As previous reports demonstrated
that the use of specific chemokine receptors is dependent on
the viral strain and target cells, a panel of viral isolates was
studied, including HIV-1ADA (derived from AIDS patient
PBMC), HIV-1JR-FL, and HIV-1YU-2 (derived from virus-infected brain tissue). Antibodies to OKT4A and AZT inhibited
HIV-1 infection of both monocytes and microglia by all viral
isolates (Fig. 5C and F, Fig. 6C and F, and Fig. 7C and F).
Interestingly, the b chemokines studied, MIP-1a, MIP-1b,
RANTES, and eotaxin, produced a minimal enhancement of
HIV-1ADA infection of monocytes (Fig. 5A and B). When
HIV-1ADA was inoculated into microglia, MIP-1b produced a
partial inhibition of reverse transcription (Fig. 5D), whereas
MIP-1a, RANTES, and eotaxin did not affect viral production.
Antibodies to CCR3 (7B11) increased HIV-1ADA replication
in monocytes but did not alter microglial infection (Fig. 5C). In
contrast to the observations described above, antibodies to
CCR5 (3A9) abrogated HIV-1ADA infection of monocytes.
However, in microglia, 3A9 only delayed the onset of productive viral replication. The peak RT values of microglia exposed
to virus and 3A9 were comparable to those of microglia exposed to virus alone (Fig. 5C and F).
For HIV-1YU-2-exposed monocytes, MIP-1a and MIP-1b
produced only a partial inhibition of virus production; however, no alterations in RT production were observed in similarly exposed microglia (Fig. 6A and D). RANTES produced
minimal increases in the levels of HIV-1YU-2 replication in
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FIG. 3. Distribution of chemokine receptors on cells in human brain tissue. Eight-micrometer-thick serial frozen sections were cut from human brain tissue obtained
at autopsy from patients with HIV-1 encephalitis (three cases) or seronegative controls (two cases). Double immunostaining was performed in order to identify the cells
expressing chemokine receptors. Microglial cells were double immunopositive for CCR3 (A) and HAM-56 (B). These cells also expressed CCR5 (C) and HAM-56 (D).
Astrocytes showed CCR3 (E) and GFAP antigens (F) but were negative for CCR5 (G and H). Panels A and B show double immunostaining with antibodies to CCR5
(5C7) and HAM-56; panels E and F show double immunostaining with antibodies to CCR3 (7B11) and GFAP; panels G and H show double immunostaining with
antibodies to CCR5 (5C7) and GFAP. Original magnifications, 3400 (panels A to D and G and H) and 3200 (panels E and F). The cellular antigens are visualized
by IF assay. The results are representative for the five brain tissue specimens examined. Identical results were found for both control and encephalitic brains.

monocytes and microglia, whereas eotaxin did not alter RT
levels in either cell type (Fig. 6B and E). Antibodies to CCR3
(7B11) increased RT levels in both monocytes and microglia
exposed to HIV-1YU-2, whereas 3A9 inhibited infection in
monocytes but not microglia. In microglia exposed to HIV1YU-2, antibodies to CCR5 delayed the onset of viral replication only. Peak RT values were similar in 3A9- and control
HIV-1YU-2-inoculated microglial cultures (Fig. 6C and F).
For HIV-1JR-FL, MIP-1a and -b produced a partial inhibition of viral replication in monocytes, whereas in microglia
MIP-1a produced a partial inhibition and MIP-1b merely delayed the onset of RT production (Fig. 7A and D). Interestingly, RANTES increased RT levels in monocyte and microglial cultures infected with HIV-1JR-FL, whereas eotaxin, the
CCR3 ligand, produced a partial inhibition (Fig. 7B and E).
Consistently, antibodies to CCR3 minimally inhibited virus
production in both monocytes and microglia. In contrast to the
other viral strains, antibodies to CCR5 (3A9) markedly reduced RT production in both monocytes and microglia exposed to HIV-1JR-FL (Fig. 7C and F).
DISCUSSION
Mononuclear phagocytes are a major reservoir for HIV-1 in
its infected human host (19). Of all tissue macrophages, microglia remain one of the most common nonlymphoid reservoirs for HIV-1 (13). Long-term effective antiviral therapies,
especially those that target viral entry, will need to take into
account the importance of such cells as long-term reservoirs
for persistent virus production. Importantly, macrophage-

tropic strains easily infect microglia. Indeed, we have shown, in
the companion paper, that a panel of divergent HIV-1 strains
infect monocytes and microglia at equal efficiencies (20).
Whether the two types of cells utilize identical coreceptors for
HIV-1 remained in question. To research this question, we
examined, side by side, the role of b-chemokine receptors for
HIV-1 infection of monocytes and microglia. A panel of neurotropic and macrophage-tropic viral isolates was used to limit
questions of HIV-1 heterogeneity and specific target cell
tropism. Surprisingly, our results demonstrated that the chemokine receptors used for HIV-1 entry into monocytes and
microglia are distinct. Whereas CCR5 was utilized as the predominant coreceptor by HIV-1 for monocytes, this was not
demonstrated for microglial infection. Of the panel of isolates
used for viral inoculation, antibodies to CCR5 restricted only
HIV-1JR-FL infection of microglia.
In a previous report by He and colleagues (23) the authors
suggested that both CCR5 and CCR3 facilitated HIV-1 infection of microglia and that CCR5 was critical for viral infection
in monocytes. The study was distinct from what was performed
in this report in several respects. First, the investigators used
mixed cultures of brain cells where microglial cells were only a
minor fraction (,5%) of the total evaluated. Second, the levels
of viral production in the control unmanipulated cells were at
or near the levels of detection by RT assays. Third, heterologous reporter gene systems used in the analyses permitted the
evaluation of only single cycles of viral replication. Fourth, we
demonstrated in this study that astrocytes express CCR3; such
cells can support limited viral replication and were the pre-

FIG. 4. Synthesis of viral nucleic acids in HIV-1-infected monocytes. Adherent monolayers of .98%-pure monocytes (3 3 106 cells/well in a six-well plate) were
infected with cell-free stocks of HIV-1YU-2 in the presence of chemokine peptides or antibodies as described in Materials and Methods. AZT (5 mM) was used as a
negative control. Control infected and uninfected cells were maintained in parallel. Chemokine peptides were used at 100 and 200 ng/ml postinfection. At 8 and 96 h
postinfection, samples were withdrawn for RT analysis and the cells were used for extraction of cellular DNA. PCR was performed to identify early (primers to LTR
U3/R), intermediate (primers to pol I and J), and late (primers to LTR U3/gag regions of viral genome) products of reverse transcription. Standard HIV-1 cDNA was
extracted from 8e5 cells that harbor a defective HIV-1 provirus. Tubulin was used as an internal standard. Amplified products of viral nucleic acids synthesized in
HIV-1-infected cultured monocytes were hybridized to radiolabeled oligonucleotide probes and quantified on a PhosphorImager (Molecular Dynamics). Data for
reverse transcription products for HIV-1YU-2 in the presence of the panel of b-chemokine receptor and CD4 antibodies and b-chemokine peptides are shown.
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FIG. 5. Effect of b-chemokine peptides and receptor antibodies on replication profiles of HIV-1ADA. Adherent monolayers of microglia (5 3 104 cells/well in a
96-well plate) and monocytes (105 cells/well) were cultured for 7 days before infection with cell-free stocks of HIV-1ADA. Prior to infection, cells were incubated with
antibodies to CCR3 (7B11; 20 mg/ml), CCR5 (3A9; 100 mg/ml), CD4 (OKT4A; 10 mg/ml), or the b-chemokine peptides MIP-1a, MIP-1b, RANTES, and eotaxin (500
ng/ml each) for 1 h at 37°C. Control infected and uninfected cells were maintained simultaneously. The infection proceeded for 4 h after which the virus was washed
off and the cells were maintained with media supplemented with appropriate concentrations of antibodies as described in Materials and Methods. Culture supernatant
samples were collected twice weekly over a period of 4 weeks postinfection. Each experimental condition was assayed in triplicate, and RT activity was measured
independently for each obtained sample.

dominant cell type in the mixed glial cultures (40) used in the
He study (23). These cells were absent in our system because
of the high level of microglial purity. This provides several
likely explanations for the discrepant results. Clearly, in pure
cultures of microglia, as used in this study, CCR3 is not an
obligatory coreceptor for infection by macrophage-tropic
HIV-1 strains. Indeed, the blocking CCR3 antibodies utilized
in our culture systems were ineffective at affecting viral entry
into both monocytes and microglia.
Interestingly, all chemokine peptides tested failed to inhibit
viral infection. This was an unexpected finding given that these
molecules were identified as suppressive factors for virus (6).
They appear to act through the HIV-1 V3 domain rather than
the regular signal transduction pathways of the viral receptors
(7). Nonetheless, there is controversy regarding the competitive inhibition of HIV-1 infection in monocytes by the chemokine receptor ligands and peptides. Schmidtmayerova et al.
(37) found that MIP-1a, MIP-1b, and RANTES led to higher
levels of replication in monocytes infected with viral isolates
92US657 and 92US660 than in untreated controls. Dragic et al.
(15) also reported a lack of inhibition of infection by chemokines in heterologous systems on the basis of single-cycle in-

fection analysis. However, Verani et al. (42) reported that
RANTES (the most potent of the chemokine peptides) produced an inhibition of infection of monocytes by HIV-1BAL.
Thus, there is a lack of consistency regarding the inhibition of
HIV-1 infection by chemokine peptides. On balance, by using
a highly purified set of cell isolation systems, two independent
cell types for viral inoculation (monocytes and microglia), and
three different HIV-1 isolates, it was found that the b-chemokine peptides consistently failed to affect viral infection in
mononuclear phagocytes. Moreover, the specific HIV-1 isolate
may have played a role in such interactions, as in this report,
MIP-1a produced an enhancement of the synthesis of viral
cDNA when monocytes were infected with HIV-1ADA but not
with HIV-1YU-2.
There is overwhelming evidence that suggests that the chemokine receptors play an important role in HIV-1 disease
progression (8–10, 25, 28, 32, 34, 36). However, the exact
mechanism by which they do so remains uncertain. It was
reported that a RANTES derivative produced potent inhibition of HIV-1 infectivity in monocytes (39). Given the resistance of individuals homozygous for CCR5 deletion to disease
progression (28, 36), the refractory nature of cells isolated
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FIG. 6. Effect of b-chemokine peptides and receptor antibodies on replication profiles of HIV-1YU-2. Adherent monolayers of microglia (5 3 104 cells/well in a
96-well plate) and monocytes (105 cells/well) were cultured for 7 days before infection with cell-free stocks of HIV-1YU-2. Prior to infection, cells were incubated with
antibodies to CCR3 (7B11; 20 mg/ml), CCR5 (3A9; 100 mg/ml), CD4 (OKT4A; 10 mg/ml), or the b-chemokine peptides MIP-1a, MIP-1b, RANTES, and eotaxin (500
ng/ml each) for 1 h at 37°C. Control infected and uninfected cells were maintained simultaneously. The infection proceeded for 4 h after which the virus was washed
off and the cells were maintained with media supplemented with appropriate concentrations of antibodies as described in Materials and Methods. Culture supernatant
samples were collected twice weekly over a period of 4 weeks postinfection. Each experimental condition was assayed in triplicate, and RT activity was measured
independently for each obtained sample.

from such individuals to infection in vitro (34), the synthesis of
chemokines as suppressor factors for HIV-1 infection (6, 7),
the changes in coreceptor usage with disease progression (9),
and the discrepant data regarding the extent of competitive
inhibition of cellular infection by chemokine receptor antibodies and receptor ligands (15, 31, 37, 42), the complexity of the
issue is further demonstrated. It may be that the HIV-1 infection of microglia proceeds through other receptors. Recently,
it has been reported that there are at least six members of the
chemokine receptor family that function in HIV-1 entry:
CCR5, CXCR4, CCR2b, CCR3, Bonzo, and BOB (12, 38).
The role of these other receptors in microglia infection remains to be elucidated. Differences in fetal (as described in this
report) and adult microglia may also be important for HIV-1
coreceptor usage.
It is generally accepted that the clinical manifestations of
HIV dementia are accompanied pathologically by an infiltration and recruitment of monocytes through the blood-brain
barrier (21). These cells, together with the resident microglia,
are the cellular targets for HIV-1 infection of the brain (19).
The lack of a cause-and-effect relationship between the levels of virus and the progression of disease in the CNS has

further supported the notion that it is the inflammatory neurotoxins produced from immunologically activated mononuclear phagocytes that produce clinical neurological disease.
Thus, the greater the numbers of these neurotoxin-producing
cells the faster the disease progression (21). Chemokines likely
play an important role in the recruitment and infiltration of
circulating blood monocytes into the CNS. Given the possibility that virus is transmitted in tissues through monocytes moving throughout the body yet undetected by the immune system,
the Trojan horse hypothesis (22), a reduced recruitment of
monocytes in the brain could facilitate the reduction of resident microglial infection.
Individuals homozygous for the CCR5 D32 allele may be
resistant to neurological disease progression due to reduced
infection of brain macrophages, to alternative (less efficient)
chemokine receptors for viral entry being utilized, or perhaps
to alterations in monocyte recruitment into the brain (41).
These events clearly are not mutually exclusive. The concept of
alternative chemokine receptors for microglial infection may
be significant, as HIV-1-neurovirulent strains may utilize receptors other than CCR3 and CCR5 as viral coreceptors for
microglial infection. Indeed, our data suggest that both mono-
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FIG. 7. Effect of b-chemokine peptides and receptor antibodies on replication profiles of HIV-1JR-FL. Adherent monolayers of microglia (5 3 104 cells/well in a
96-well plate) and monocytes (105 cells/well) were cultured for 7 days before infection with cell-free stocks of HIV-1JR-FL. Prior to infection, cells were incubated with
antibodies to CCR3 (7B11; 20 mg/ml), CCR5 (3A9; 100 mg/ml), CD4 (OKT4A; 10 mg/ml), or the b-chemokine peptides MIP-1a, MIP-1b, RANTES, and eotaxin (500
ng/ml each) for 1 h at 37°C. Control infected and uninfected cells were maintained simultaneously. The infection proceeded for 4 h after which the virus was removed
and the cells were maintained with media supplemented with antibodies as described above. Culture supernatant samples were collected twice weekly over a period
of 4 weeks following infection. Each experimental condition was assayed in triplicate, and RT activity was measured independently for each obtained sample.

cytes and microglia are capable of supporting HIV-1 infection
with strains that do not utilize CCR3. We, therefore, hypothesize that other chemokine receptors may be responsible for
the evolution of microglia-tropic strains of HIV-1 leading to
progressive neurological impairments seen during advanced
clinical disease.
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